Production of donor-derived cytotoxic T lymphocytes with potent anti-leukemia activity for adoptive immunotherapy in high-risk pediatric patients given haploidentical hematopoietic stem cell transplantation.

Matteo TanziEnrica MontiniAgnese RumoloAntonia MorettaPatrizia ComoliGloria AcquafreddaJessica RotellaGloria TaurinoFrancesca CompagnoFrancesco Delle CaveCesare PerottiGian Luigi MarsegliaMarco ZeccaDaniela Montagna

Published in: Cytotherapy (2024)

These results demonstrated that our protocol is highly reproducible and allows the generation of large numbers of immunologically safe and functional anti-leukemia CTL with a high level of standardization.

Keyphrases

acute myeloid leukemia
bone marrow
randomized controlled trial
cell therapy
stem cell transplantation
peripheral blood
stem cells
mesenchymal stem cells
low dose
cord blood